FDA will ask its Anesthetic and Analgesic Drug Products Advisory Committee on June 11-12 to consider whether a possible association exists between opioid withdrawal and an increased risk of cardiovascular adverse events with chronic use of peripherally active mu opioid receptor antagonists.
The agency is requesting the committee discuss whether the totality of data suggests a CV safety signal for the class...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?